Haematologica

Article	Citations
Pediatric acute lymphoblastic leukemia	250
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy	185
International recommendations on the diagnosis and treatment of acquired hemophilia A	170
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma	127
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia	92
Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia	92
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukem	88
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma	86
Donor sex, age and ethnicity impact stored red blood cell antioxidant metabolism through mechanisms in part explained by glucose 6-phosphate dehydrogenase levels and activity	85
Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial	84
One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors	82
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens	74
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia	73
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma	72
Multiple myeloma: the (r)evolution of current therapy and a glance into future	70
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models	70
Acquired von Willebrand syndrome: focused for hematologists	67
Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion	63
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition	61
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide	61
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study	61
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT	58
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study	58
History of hematopoietic cell transplantation: challenges and progress	55
Geriatric assessment in older patients with a hematologic malignancy: a systematic review	54

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE t	54
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis	51
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria	51
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia	50
Complement C5 inhibition in patients with COVID-19 - a promising target?	50
Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies	47
Post-mortem findings in vaccine-induced thrombotic thombocytopenia	47
Myelodysplastic syndromes: moving towards personalized management	47
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study	47
ABO blood groups are not associated with risk of acquiring the SARS-CoV-2 infection in young adults	46
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies	46
A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies	46
Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age	45
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients	44
MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma	44
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913	43
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression	43
Inherited thrombocytopenias: history, advances and perspectives	43
Heme induces human and mouse platelet activation through C-type-lectin-like receptor-2	42
Potential targeting of FLT3 acute myeloid leukemia	42
Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing αβ T cell-depleted haploidentical hematopoietic stem cell transplantation	42
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma	42
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome	41
VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome)	41
Targeting the tumor microenvironment in chronic lymphocytic leukemia	41
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk	41
Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance	41
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma	40
Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients	39
The interactome of the N-terminus of band 3 regulates red blood cell metabolism and storage quality	39
Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target	39
Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS	38
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells	38
Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany	37
Red cell transfusion and alloimmunization in sickle cell disease	37
miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis	37
Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation o	36
Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy	36
Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021?	36
Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial	35
A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis	34
<i>In vitro</i> and <i>in vivo</i> induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor	34
Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study	34
Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines	33
Multiple myeloma with central nervous system relapse	33
Complement dysregulation is associated with severe COVID-19 illness	33
A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol	33
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome	32
Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma	32
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas	32

The molecular basis for the prothrombotic state in sickle cell disease	31
Unique ethnic features of <I>DDX41</I> mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia	31
Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York	31
Maintenance therapy for <i>FLT3-ITD</i>-mutated acute myeloid leukemia	30
No evidence of hemoglobin damage by SARS-CoV-2 infection	30
Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood s	30
Molecular heterogeneity of pyruvate kinase deficiency	30
<i>DUX4r</i>, <i>ZNF384r</i> and <i>PAX5</i>-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch	30
Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis	30
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation	30
The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia	29
Hemostatic alterations in COVID-19	29
To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia	29
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies	28
Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding	28
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma	28
COVID-19 and sickle cell disease	28
IgM monoclonal gammopathies of clinical significance: diagnosis and management	28
The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy	28
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape	28
Leukemic stem cells and therapy resistance in acute myeloid leukemia	27
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia	27
COVID-19 in patients with sickle cell disease - a case series from a UK Tertiary Hospital	27
Circulating histones play a central role in COVID-19-associated coagulopathy and mortality	27
Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia	27
Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma	27
The variable manifestations of disease in pyruvate kinase deficiency and their management	27
Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy	26
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated <i>E. coli</i> asparaginase in children with acute lymphocytic leuke	26
Molecular and phenotypic diversity of <I>CBL</I>-mutated juvenile myelomonocytic leukemia	26
Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease	26
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?	26
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma	26
Successful pregnancies after transplantation of ovarian tissue retrieved and cryopreserved at time of childhood acute lymphoblastic leukemia – A case report	25
Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways	25
Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia	24
Endothelial damage and dysfunction in acute graft-versus-host disease	24
Dramatic presentation of acquired thombotic thrombocytopenic purpura associated with COVID-19	24
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis	24
The clinical impact of the molecular landscape of acute myeloid leukemia	24
Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome	24
Bile acids regulate intestinal antigen presentation and reduce graft-versus-host disease without impairing the graft-versus-leukemia effect	24
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)	24
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study	24
Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia	24
BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy	23
Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter	23
Ddx41 inhibition of DNA damage signaling permits erythroid progenitor expansion in zebrafish	23
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma	23
Immunological consequences of extramedullary erythropoiesis: immunoregulatory functions of CD71+ erythroid cells	23
Beta thalassemia minor is a beneficial determinant of red blood cell storage lesion	23
Stored blood has compromised oxygen unloading kinetics that can be normalized with rejuvenation and predicted from corpuscular side-scatter	23
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study	22
Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease	22
Aging of human hematopoietic stem cells is linked to changes in Cdc42 activity	22
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute l	22
Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies	21
The present and future of measurable residual disease testing in acute myeloid leukemia	21
DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study	21
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study	21
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde	21
Mortality in children with sickle cell disease in mainland France from 2000 to 2015	21
Marginal zone lymphoma: present status and future perspectives	21
Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma	21
Novel immunotherapies in multiple myeloma – chances and challenges	21
A genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways that mediate resistance to sorafenib in acute myeloid leukemia	20
TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma	20
Bone marrow niche dysregulation in myeloproliferative neoplasms	20
Cytoskeletal-based mechanisms differently regulate <i>in vivo</i> and <i>in vitro</i> proplatelet formation	20
Impaired microRNA processing in neutrophils from rheumatoid arthritis patients confers their pathogenic profile. Modulation by biological therapies	20
Whole exome sequencing identifies mutational signatures of vitreoretinal lymphoma	20
Translational and clinical advances in acute graft-versus-host disease	20
Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia	20
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome	20
Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study	20
Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies	20
CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients	20
Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model	19
<i>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)	19
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia	19

Genetic evolution of <i>in situ</i> follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype	19
Comparison of CD38 antibodies <i>in vitro</i> and <i>ex vivo</i> mechanisms of action in multiple myeloma	19
CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity	19
Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations	19
Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease	19
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma	19
XPO1 regulates erythroid differentiation and is a new target for the treatment of β-thalassemia	19
Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia	19
Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis	19
Deregulation of JAK2 signaling underlies primary cutaneous CD8<sup>+</sup> aggressive epidermotropic cytotoxic T-cell lymphoma	19
Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients	18
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results	18
The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis	18
T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective	18
The TRPV2 channel mediates Ca2+ influx and the Δ9-THC-dependent decrease in osmotic fragility in red blood cells	18
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies	17
Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets	17
Glenzocimab does not impact glycoprotein VI-dependent inflammatory hemostasis	17
Novel reciprocal fusion genes involving HNRNPC and RARG in acute promyelocytic leukemia lacking RARA rearrangement	17
Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia	17
Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag	17
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration	17
Treatment of drug-induced immune thrombocytopenias	17
Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia who have been treated with blinatumomab	17
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study	17
Clonal independence of <i>JAK2</i> and <i>CALR</i> or <i>MPL</i> mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing	17
Towards manufactured red blood cells for the treatment of inherited anemia	17
Kikuchi-Fujimoto disease associated with hemophagocytic lymphohistiocytosis following the BNT162b2 mRNA COVID-19 vaccination	17
Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents	17
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies	17
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades	17
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an <i>ad hoc</i> expert panel	16
The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial	16
Perforin gene variant A91V in young patients with severe COVID-19.	16
The Hsp70 chaperone system: distinct roles in erythrocyte formation and maintenance	16
Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse	16
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome	16
A 3D iPSC-differentiation model identifies interleukin-3 as a regulator of early human hematopoietic specification	16
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas	16
Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis	16
Characterization of freshly isolated bone marrow mesenchymal stromal cells from healthy donors and patients with multiple myeloma: transcriptional modulation of the microenvironment	16
Dominance of an <i>UBA1</i> mutant clone over a <i>CALR</i> mutant clone: from essential thrombocytemia to VEXAS.	16
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis	16
Baseline SUV<sub>max</sub> is related to tumor cell proliferation and patient outcome in follicular lymphoma	16
Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation	16
Protein-L-isoaspartate O-methyltransferase is required for <i>in vivo</i> control of oxidative damage in red blood cells	16
Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance.	16
Prevention and management of secondary central nervous system lymphoma	16
PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia	16
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial	16
Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis	15
A frequent nonsense mutation in exon 1 across certain HLA-A and -B alleles in leukocytes of patients with acquired aplastic anemia	15
Immune-mediated thrombotic thrombocytopenic purpura following administration of Pfizer-BioNTech COVID-19 vaccine	15
Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature	15
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)	15
The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma	15
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study	15
Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis- related graft failure and disseminated bacillus Calmette-Guérin infection	15
Circulating cell-free <i>BRAF</i> V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis	15
Crucial role of hematopoietic <i>JAK2</i> V617F in the development of aortic aneurysms	15
Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia	15
IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib	15
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities	15
Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications	15
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project	15
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation	15
Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing	15
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study	15
Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia	15
Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes	14
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial	14
Excellent proliferation and persistence of allogeneic donor-derived 41-BB based CAR-T cells despite immunosuppression with cyclosporine A	14
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients	14
Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia	14
Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications	14
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma	14
Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy	14
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients	14
Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial	14
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial	14
SARS-CoV-2 infection in aplastic anemia	14
Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia	14
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia	14
Post-translational polymodification of β1-tubulin regulates motor protein localization in platelet production and function	14
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis	14
A novel classification of hematologic conditions in patients with Fanconi anemia	14
Untargeted metabolic profiling in dried blood spots identifies disease fingerprint for pyruvate kinase deficiency	14
Differentiation therapy of myeloid leukemia: four decades of development	14
Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia	14
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study	13
Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma	13
The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias	13
Acute myeloid leukemia shapes the bone marrow stromal niche <i>in vivo</i>	13
DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome	13
A risk score based on real-world data to predict early death in acute promyelocytic leukemia	13